Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

105

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
11/08/26	€0.1800	0.00%	4,150
10/08/26	€0.1800	+5.88%	5,800
07/08/26	€0.1700	+30.77%	62,306
06/08/26	€0.1300	0.00%	4,900
05/08/26	€0.1300	-1.52%	22,450

Delayed Quote Börse Stuttgart

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1860USD

Average target price

1.000USD

Spread / Average Target

+437.63%

Consensus

Annual profits - Rate of surprise

Company calendar

Delayed Börse Stuttgart Other stock markets 18:47:24 11/08/2026 BST			5-day change	1st Jan Change
0.1800 ^EUR	0.00%		+36.36%	-12.62%

08-06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI

Market Cap	314M 272M 255M 232M 437M 29.95B 445M 2.99B 1.17B 14.99B 1.18B 1.15B 50.01B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	410M 355M 333M 304M 571M 39.11B 581M 3.9B 1.53B 19.58B 1.54B 1.51B 65.31B	EV / Sales 2026 *	-	EV / Sales 2027 *	11.3x
Free-Float	95.3%	Yield 2026 *	-	Yield 2027 *	-

08-06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
26/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
23/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
26/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
18/08/25	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI

08-06	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
04-30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR

Northwest Biotherapeutics, Inc. Share Price Börse Stuttgart

Stocks

NBYB

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Chart: Northwest Biotherapeutics, Inc.

Latest news : Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

1 week	+36.36%
Current month	+34.33%
1 month	+12.50%
6 months	-18.18%
Current year	-12.62%

1 week	0.12	0.22
1 month	0.1	0.22
Current year	0.1	0.38
1 year	0.1	0.38
3 years	0.1	1.02
5 years	0.1	2.18
10 years	0.1	2.18

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	31/05/2007
Linda Powers CEO	Chief Executive Officer	71	07/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	31/12/1999

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	31/12/1997
Linda Powers CHM	Chairman	71	16/05/2007
Navid Malik BRD	Director/Board Member	57	31/03/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	0.00%	+36.36%	-	-	314M
WUXI APPTEC CO., LTD.	-0.70%	+24.68%	+76.72%	+103.05%	70.85B
ARGENX SE	-2.35%	+2.88%	+35.39%	+64.72%	55.41B
INSMED INCORPORATED	-0.99%	+35.75%	+18.74%	+497.64%	29.43B
WUXI BIOLOGICS (CAYMAN) INC.	-0.30%	+18.51%	+56.61%	+4.86%	24.12B
BIONTECH SE	-0.37%	+0.85%	-15.68%	-13.83%	23.31B
GENMAB A/S	+0.05%	+6.12%	+46.81%	-21.81%	18.37B
PHARMAESSENTIA CORPORATION	+9.77%	+25.32%	+252.40%	+442.16%	16.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	0.00%	+10.84%	+31.14%	+628.97%	16.1B
EXELIXIS, INC.	-2.11%	-7.48%	+38.49%	+140.75%	13.12B
Average	+0.31%	+390.71%	+60.07%	+205.17%	29.75B
Weighted average by Cap.	-0.32%	+349.16%	+56.42%	+165.90%

	2026 *	2027 *
Net sales	-	38.93M 33.74M 31.59M 28.82M 54.23M 3.71B 55.15M 370M 145M 1.86B 146M 143M 6.2B
Net income	-	-
Net Debt	96.08M 83.26M 77.95M 71.12M 134M 9.16B 136M 914M 358M 4.59B 361M 353M 15.3B	125M 108M 101M 92.48M 174M 11.92B 177M 1.19B 466M 5.96B 469M 459M 19.9B